$DSGN
Design Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024055788 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.527M $4.599M
YoY Change -18.17% -22.33%
% of Gross Profit
Research & Development $10.52M $9.801M
YoY Change -38.37% -37.69%
% of Gross Profit
Depreciation & Amortization $151.0K $143.0K
YoY Change 13.53% 10.85%
% of Gross Profit
Operating Expenses $15.04M $14.40M
YoY Change -33.43% -33.49%
Operating Profit -$15.04M -$14.40M
YoY Change -33.43% -33.49%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.250M $3.295M
YoY Change 22.23% 39.8%
Pretax Income -$11.79M -$11.11M
YoY Change -40.85% -42.44%
Income Tax
% Of Pretax Income
Net Earnings -$11.79M -$11.11M
YoY Change -40.85% -42.44%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21 -$0.20
Diluted Earnings Per Share -$0.21 -$0.20
COMMON SHARES
Basic Shares Outstanding 56.50M 56.49M
Diluted Shares Outstanding 56.56M 56.49M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $261.0M $270.7M
YoY Change -13.88% -14.17%
Cash & Equivalents $45.70M $29.40M
Short-Term Investments $215.3M $241.3M
Other Short-Term Assets $2.428M $1.524M
YoY Change -17.89% -57.03%
Inventory
Prepaid Expenses $2.428M $1.524M
Receivables
Other Receivables
Total Short-Term Assets $264.8M $273.9M
YoY Change -13.46% -14.13%
LONG-TERM ASSETS
Property, Plant & Equipment $1.728M $1.718M
YoY Change -7.15% -9.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $429.0K $427.0K
YoY Change -3.38% -5.53%
Total Long-Term Assets $4.740M $4.907M
YoY Change -15.13% -15.45%
TOTAL ASSETS
Total Short-Term Assets $264.8M $273.9M
Total Long-Term Assets $4.740M $4.907M
Total Assets $269.6M $278.8M
YoY Change -13.49% -14.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.297M $1.372M
YoY Change -32.52% -50.0%
Accrued Expenses $5.097M $5.722M
YoY Change -50.08% -9.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.394M $7.094M
YoY Change -47.3% -21.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.946M $2.142M
YoY Change -27.98% -25.57%
Total Long-Term Liabilities $1.946M $2.142M
YoY Change -27.98% -25.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.394M $7.094M
Total Long-Term Liabilities $1.946M $2.142M
Total Liabilities $8.340M $9.236M
YoY Change -43.78% -22.55%
SHAREHOLDERS EQUITY
Retained Earnings -$200.5M -$188.7M
YoY Change 33.67% 45.04%
Common Stock $462.0M $458.5M
YoY Change 2.94% 3.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $261.2M $269.6M
YoY Change
Total Liabilities & Shareholders Equity $269.6M $278.8M
YoY Change -13.49% -14.15%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$11.79M -$11.11M
YoY Change -40.85% -42.44%
Depreciation, Depletion And Amortization $151.0K $143.0K
YoY Change 13.53% 10.85%
Cash From Operating Activities -$11.26M -$12.44M
YoY Change -18.43% -28.61%
INVESTING ACTIVITIES
Capital Expenditures $161.0K $195.0K
YoY Change 80.9% 124.14%
Acquisitions
YoY Change
Other Investing Activities $27.49M $20.81M
YoY Change 127.77% 5.0%
Cash From Investing Activities $27.33M $20.62M
YoY Change 128.12% 4.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 229.0K 20.00K
YoY Change 9.05%
NET CHANGE
Cash From Operating Activities -11.26M -12.44M
Cash From Investing Activities 27.33M 20.62M
Cash From Financing Activities 229.0K 20.00K
Net Change In Cash 16.30M 8.197M
YoY Change -1111.29% 255.0%
FREE CASH FLOW
Cash From Operating Activities -$11.26M -$12.44M
Capital Expenditures $161.0K $195.0K
Free Cash Flow -$11.42M -$12.63M
YoY Change -17.79% -27.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001807120
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40288
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Design Therapeutics, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3929248
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
6005 Hidden Valley Road
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 110
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92011
CY2024Q1 dei City Area Code
CityAreaCode
858
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
293-4900
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
DSGN
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56495039
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29397000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21200000
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
241289000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
260598000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3200000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2786000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
273886000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
284584000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1718000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1691000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2762000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2938000
CY2024Q1 us-gaap Other Assets
OtherAssets
427000
CY2023Q4 us-gaap Other Assets
OtherAssets
430000
CY2024Q1 us-gaap Assets
Assets
278793000
CY2023Q4 us-gaap Assets
Assets
289643000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1372000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1940000
CY2024Q1 dsgn Accrued Expenses And Other Current Liabilities Related Parties Current
AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent
736000
CY2023Q4 dsgn Accrued Expenses And Other Current Liabilities Related Parties Current
AccruedExpensesAndOtherCurrentLiabilitiesRelatedPartiesCurrent
716000
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5722000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7682000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7094000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9622000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2142000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2334000
CY2024Q1 us-gaap Liabilities
Liabilities
9236000
CY2023Q4 us-gaap Liabilities
Liabilities
11956000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56494271
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56494271
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56473598
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56473598
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
458449000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
455245000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188731000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-177626000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-167000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
62000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
269557000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
277687000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278793000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
289643000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9801000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15730000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4599000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5921000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
14400000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
21651000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14400000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21651000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3295000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2357000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11105000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-19294000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56488527
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56488527
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55908033
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55908033
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11105000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-19294000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-229000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1374000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11334000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17920000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
277687000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3184000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-229000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11105000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
269557000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
327310000
CY2023Q1 dsgn Stock Issued During Period Value Stock Options Exercised And Vesting Of Early Exercised Common Stock Options
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfEarlyExercisedCommonStockOptions
2000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3426000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1374000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-19294000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
312818000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-11105000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-19294000
CY2024Q1 us-gaap Depreciation
Depreciation
143000
CY2023Q1 us-gaap Depreciation
Depreciation
129000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3184000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3426000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1731000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1142000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
10000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
411000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1192000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-2523000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-1745000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12439000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17424000
CY2024Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
45659000
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
33615000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
66470000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
53435000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
195000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
87000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20616000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19733000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8197000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2309000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21200000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26500000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29397000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28809000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="organization" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Orga</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Design Therapeutics, Inc. (the “Company”) was incorporated in Delaware in December 2017 and is based in Carlsbad, California. The Company is a biopharmaceutical company pioneering the research and development of GeneTAC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s lead product candidate is in Friedreich ataxia (“FA”), its second product candidate is in Fuchs endothelial corneal dystrophy (“FECD”), and it is also advancing GeneTAC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">programs to address other diseases.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses since inception and had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">188.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of March 31, 2024. The Company had cash, cash equivalents and investment sec</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">urities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">270.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2024, and has not generated positive cash flow from operations.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management expects to incur net losses for the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the research, product development and clinical development activities as well as the commercialization of the Company's products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. The Company's currently available cash and cash equivalents as of March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are sufficient to meet its anticipated cash requirements for more than 12 months following the date the financial statements are issued.</span>
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188700000
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
270700000
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10823790
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7986754
CY2024Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
268686000
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
280217000
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
241456000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
90000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
257000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
241289000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
260536000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
498000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
436000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
260598000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
93
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
71
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
141476000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
153000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
33245000
CY2024Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
104000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
174721000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
257000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
65344000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
132000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
60908000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
304000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
126252000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
436000
CY2024Q1 dsgn Number Of Domestic Certificates Of Deposit Held
NumberOfDomesticCertificatesOfDepositHeld
53
CY2024Q1 dsgn Accrued Interest Receivable On Available For Sale Investment Securities
AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities
1700000
CY2023Q4 dsgn Accrued Interest Receivable On Available For Sale Investment Securities
AccruedInterestReceivableOnAvailableForSaleInvestmentSecurities
1400000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1524000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1354000
CY2024Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
1676000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1432000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3200000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2786000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2920000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2750000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1202000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1059000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1718000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1691000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2069000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4034000
CY2024Q1 dsgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2341000
CY2023Q4 dsgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2350000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
736000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
716000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
576000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
582000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5722000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7682000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
690000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
945000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
973000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
663000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3271000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
393000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2878000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8561753
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.67
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2497450
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.55
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20673
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.95
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
328082
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.52
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10710448
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.11
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3184000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3426000
CY2023Q3 dsgn Type Of Stock Options Granted To Purchase Common Stock
TypeOfStockOptionsGrantedToPurchaseCommonStock
2

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
dsgn-20240331_htm.xml Edgar Link completed
0000950170-24-055788-index-headers.html Edgar Link pending
0000950170-24-055788-index.html Edgar Link pending
0000950170-24-055788.txt Edgar Link pending
0000950170-24-055788-xbrl.zip Edgar Link pending
dsgn-20240331.htm Edgar Link pending
dsgn-20240331.xsd Edgar Link pending
dsgn-ex31_1.htm Edgar Link pending
dsgn-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending